Melatonin ameliorates aging-related impaired angiogenesis in gastric endothelial cells via local actions on mitochondria and VEGF-survivin signaling

Am J Physiol Gastrointest Liver Physiol. 2021 Dec 1;321(6):G682-G689. doi: 10.1152/ajpgi.00101.2021. Epub 2021 Oct 20.

Abstract

Tissue injury healing is impaired in aging, and this impairment is caused in part by reduced angiogenesis. Melatonin, a neuroendocrine hormone that regulates sleep and circadian rhythm, is also produced in the gastrointestinal tract. The expression of melatonin receptors MT1 and MT2 in gastric endothelial cells and their roles in aging-related impairment of gastric angiogenesis have not been examined. We hypothesized that MT1 and MT2 expression is reduced in gastric endothelial cells of aging rats and that melatonin treatment can upregulate their expression and improve angiogenesis. We examined the expression of MT1 and MT2 in gastric endothelial cells (GECs) isolated from young and aging rats. We also examined the effects of melatonin treatment on angiogenesis, GEC mitochondrial function, expression of vascular endothelial growth factor (VEGF), its signaling receptor (VEGFR-2), and the inhibitor of apoptosis protein, survivin. Young and aging GECs expressed MT1 (in the cytoplasm and mitochondria) and MT2 (in nucleus and mitochondria). In aging GECs, MT1 and MT2 levels, in vitro angiogenesis, and mitochondrial membrane potential were significantly reduced (by 1.5-fold, 1.9-fold, 3.1-fold, and 1.63-fold, respectively) compared with young GECs. Melatonin treatment of aging GECs significantly increased MT1 and MT2 expression compared with the controls, induced nuclear translocation of MT1, and significantly ameliorated the aging-related impairment of angiogenesis and mitochondrial function. Aging GECs have significantly reduced MT1 and MT2 expression, angiogenesis, and mitochondrial membrane potential compared with young GECs. Treatment of aging GECs with melatonin increases expression of VEGF receptor and survivin and ameliorates aging-related impaired angiogenesis and mitochondrial function.NEW & NOTEWORTHY This study showed reduced expression of melatonin receptors MT1 and MT2, angiogenesis, and mitochondrial function in gastric endothelial cells (GECs) isolated from aging rats. Treatment of aging GECs with melatonin increases expression of VEGF receptor and survivin and ameliorates aging-related impaired angiogenesis and mitochondrial function. These studies provide new insight into the mechanisms of the aging-related impairment of angiogenesis and delayed tissue injury healing and provide a rationale for melatonin treatment to reverse these abnormalities.

Keywords: aging; angiogenesis; gastric endothelial cells; melatonin; melatonin receptors.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Age Factors
  • Angiogenesis Inducing Agents / pharmacology*
  • Animals
  • Cells, Cultured
  • Endothelial Cells / drug effects*
  • Endothelial Cells / metabolism
  • Gastric Mucosa / blood supply*
  • Melatonin / pharmacology*
  • Mitochondria / drug effects*
  • Mitochondria / metabolism
  • Neovascularization, Physiologic / drug effects*
  • Rats
  • Rats, Inbred F344
  • Receptor, Melatonin, MT1 / agonists
  • Receptor, Melatonin, MT1 / metabolism
  • Receptor, Melatonin, MT2 / agonists
  • Receptor, Melatonin, MT2 / metabolism
  • Signal Transduction
  • Survivin / metabolism*
  • Vascular Endothelial Growth Factor A / metabolism*

Substances

  • Angiogenesis Inducing Agents
  • Birc5 protein, rat
  • Receptor, Melatonin, MT1
  • Receptor, Melatonin, MT2
  • Survivin
  • Vascular Endothelial Growth Factor A
  • vascular endothelial growth factor A, rat
  • Melatonin